Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07260799 · ClinicalTrials.gov registry record
Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer
A clinical trial of Serum Analytes, sponsored by Tasso.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07260799 is a study of Serum Analytes that is actively recruiting participants, run by Tasso. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07260799, a study of Serum Analytes, is actively recruiting participants, sponsored by Tasso.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this single-visit study is to demonstrate the performance of capillary blood samples collected with the Tasso+ Serum Gel Capillary Blood Collection System compared to venous reference samples for downstream analyte testing at a clinical laboratory.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tasso+ Serum Gel Capillary Blood Collection System
Study Locations (1)
Florida
- Celesta / American Research Labs - Atlantis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-10-25 |
| Est. Completion | 2026-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07260799
The ClinicalTrials.gov registry entry for NCT07260799 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tasso, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Serum Analytes appearing as the primary indexed condition, and to 1 intervention - of which Tasso+ Serum Gel Capillary Blood Collection System is the first listed.
NCT07260799 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07260799 about?
NCT07260799 is a clinical study titled "Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer". The purpose of this single-visit study is to demonstrate the performance of capillary blood samples collected with the Tasso+ Serum Gel Capillary Blood Collection System compared to venous reference samples for downstream analyte testing at a clinical laboratory.
What is the current status of trial NCT07260799?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-10-25. Estimated completion is 2026-05-31.
What conditions does trial NCT07260799 study?
This clinical trial studies the following conditions: Serum Analytes.
What interventions are being tested in trial NCT07260799?
The interventions under investigation include: Tasso+ Serum Gel Capillary Blood Collection System (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07260799?
This trial is sponsored by Tasso, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07260799 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.